Alzamend Trials Novel Lithium Treatment
The company is testing a new organic lithium salt designed for better brain delivery and less toxicity. Results from a Phase 1/2A trial were presented by researchers sponsored by Alzamend at an ISMRM workshop.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed